• Dawn C Buse, Sanjay K Gandhi, Joshua M Cohen, Verena Ramirez-Campos, Blaine Cloud, Ronghua Yang, and Robert P Cowan.
• Albert Einstein College of Medicine, Bronx, NY, 10461, USA. dbuse@montefiore.org.
• J Headache Pain. 2020 Sep 4; 21 (1): 109.

BackgroundThe long-term safety and efficacy of fremanezumab were evaluated in a 52-week extension study (NCT02638103). Patient satisfaction with fremanezumab, dosing preferences, and patient-reported outcomes were assessed in a subpopulation who completed the extension study and consented to a follow-up questionnaire.MethodsIn the extension study (N = 1842), adults with migraine were randomized to quarterly or monthly fremanezumab. After completing active treatment, patients answered a survey evaluating patient satisfaction, treatment and dosing preferences, and changes in patient-reported outcomes.ResultsOf the 557 patients who could have been contacted upon completing the extension study, 302 consented and 253 completed the survey. The mean (standard deviation) satisfaction rating for fremanezumab was 6.1 (1.4; 1 = "extremely dissatisfied" to 7 = "extremely satisfied"). Most patients (175 [69.2%]) preferred quarterly over monthly fremanezumab dosing. Among patients taking antiepileptics (most common class of prior preventive medication; n = 130), 91.5% preferred fremanezumab. Patients reported improvements in anxiety (74 [67.9%]), sleep quality (143 [56.5%]), and quality of time spent with others (210 [83.0%]) with fremanezumab.ConclusionIn this study, treatment satisfaction with fremanezumab was high, most patients preferred quarterly fremanezumab dosing, and fremanezumab was generally preferred to prior preventive medications.Trial RegistrationClinicalTrials.gov NCT02638103 (HALO LTS), registered December 22, 2015.

21 keywords...

hide…